Trial Profile
A Multinational, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Activity of FP 045 in Patients With Fanconi Anemia (FusuciA Study)
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 15 Nov 2023
Price :
$35
*
At a glance
- Drugs FP-045 (Primary)
- Indications Fanconi's anaemia; Peripheral arterial disorders
- Focus Adverse reactions; Proof of concept
- Acronyms FuschiA study
- Sponsors Foresee Pharmaceuticals
- 30 Oct 2023 Planned End Date changed from 1 Dec 2024 to 1 Dec 2025.
- 30 Oct 2023 Planned primary completion date changed from 1 Jun 2024 to 1 Jun 2025.
- 30 Sep 2023 According to a Foresee Pharmaceuticals media release, study design will be presented at the Fanconi Anemia Research Fund (FARF) 2023 Scientific Symposium.